OQROGet OQRO Pro
Insider trade

Beone Medicines (ONC)CEO sold ~$1.32M

John Oyler, CEO at Beone Medicines, sold ~$1.32M of Beone Medicines shares.

~$1.32M
Approx. value · 4,066 sh @ $324.12
24K
Holds after · shares reported
Traded
Sep 16, 2025
Filed
Sep 18, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 18, 2025InsiderOfficer sold ~$210K of ONC shares in the open market
  2. Jul 29, 2025Insider · 1 personInsiders: 3 sales (~$1.2M)
  3. Jul 30, 2025Insider · 2 peopleInsiders: 2 sales (~$359K)
  4. Aug 1, 2025InsiderCFO sold ~$346K of ONC shares in the open market
  5. Aug 13, 2025Insider · 2 peopleInsiders: 11 sales (~$18.5M)
  6. Aug 14, 2025Insider · 1 personInsiders: 8 sales (~$12.2M)
  7. Sep 2, 2025InsiderOfficer sold ~$40K of ONC shares in the open market
  8. Sep 5, 2025InsiderDirector sold ~$898K of ONC shares in the open market
  9. Sep 9, 2025Insider · Their largest sale since 2021Officer sold ~$1.75M of ONC shares in the open market
  10. Sep 10, 2025Insider · 1 personInsiders: 5 sales (~$3.3M)
  11. Sep 16, 2025 · this disclosureInsiderCEO sold ~$1.32M of ONC shares in the open market

What came next

  1. Sep 16, 2025Insider · 1 personInsiders: 4 sales (~$7.7M)
  2. Nov 6, 2025Company filing · Form 8-K · ResultsReported its results
  3. Nov 13, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  4. Dec 16, 2025Company filing · Form 8-K · Agreement endedEnded an important agreement
  5. Dec 17, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 17, 2025, BeOne Medicines Ltd. (the “Company”) appointed Dr. Lai Wang to serve as President, Global Head of Research and Development of the Company.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Beone Medicines

For Beone Medicines, OQRO holds 11 insider filings (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ONC page.

Other recent filings by John Oyler, Chief Executive Officer

The full history of John Oyler, Chief Executive Officer is on the profile page.

How this filing works

Other disclosures at Beone Medicines

Everything OQRO holds on this company is on its ONC page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data